首页> 外文期刊>The journal of headache and pain >EHMTI-0279. Deep brain stimulation for refractory chronic cluster headache
【24h】

EHMTI-0279. Deep brain stimulation for refractory chronic cluster headache

机译:EHMTI-0279。深部脑刺激治疗难治性慢性丛集性头痛

获取原文
       

摘要

Chronic cluster headache (CCH) is an excruciating, unilateral headache with recurrent episodes of severe pain associated with ipsilateral autonomic features. 10-20% of patients are refractory to medical management. We present a prospective cohort of 19 patients with intractable CCH treated with posterior hypothalamic deep brain stimulation (DBS). Patients with refractory CCH referred to multidisciplinary headache clinic at our centre underwent DBS. Clinical data was collected pre and post-treatment. Headache load (HAL) (defined as [severity (on the visual analogue score)] x [duration] x [frequency] of headaches over a 2 week period) was calculated before and after treatment. A treatment response was identified as a 30% or more reduction in HAL. 19 patients (M=15) with a median age of 48 years (33-67 years) underwent surgery. Median follow up time was 12 months (9-48 months). 17 patients had at least one year follow up. Five patients failed to respond to treatment but nine showed a reduction in HAL of more than 80%. Within three months of surgery, the median change in HAL was 62% (0-100%) and at twelve months was 69% (0-100%). Significant differences exist between HAL at baseline and at three (p=0.001) and twelve months (p=0.06). There were no serious adverse events. One patient reported persistent diplopia, which was due to decompensation of a long-standing third nerve palsy. Posterior Hypothalamic DBS appears a safe and effective treatment for CCH and should be considered for suitable patients who fail conventional treatment. No conflict of interest.
机译:慢性丛集性头痛(CCH)是一种严重的单侧头痛,伴有同侧自主神经功能相关的严重疼痛反复发作。 10-20%的患者不愿接受药物治疗。我们提出了前丘脑后部深部脑刺激(DBS)治疗的19例顽固性CCH患者的前瞻性队列研究。难治性CCH患者转诊至我们中心的多学科头痛诊所接受了DBS。治疗前和治疗后收集临床数据。在治疗前后计算头痛负荷(HAL)(定义为[严重程度(在视觉模拟评分上)] x [持续时间] x [频率]在两周内的头痛)。治疗反应被确定为HAL降低30%或更多。中位年龄为48岁(33-67岁)的19例患者(M = 15)接受了手术。中位随访时间为12个月(9-48个月)。 17名患者至少接受了一年的随访。五名患者对治疗无效,但九名患者的HAL降低超过80%。在手术的三个月内,HAL的中位变化为62%(0-100%),在十二个月时为69%(0-100%)。基线和三个月(p = 0.001)和十二个月(p = 0.06)之间的HAL之间存在显着差异。没有严重的不良事件。一名患者报告称持续性复视是由于长期存在的第三神经麻痹失代偿所致。下丘脑后部DBS对于CCH似乎是一种安全有效的治疗方法,对于常规治疗失败的合适患者应予以考虑。没有利益冲突。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号